Moving beyond intent: Building more diverse clinical trials
Improving representation is not simply about increasing awareness or setting enrolment targets. It requires identifying and removing the barriers.
Newsletters and Deep Dive digital magazine
Improving representation is not simply about increasing awareness or setting enrolment targets. It requires identifying and removing the barriers.
Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.
Any gap between an AI-generated answer and a product’s approved profile carries consequences for prescribing decisions and patient safety.
CAMP4 Therapeutics CFO Kelly Gold discusses developments in antisense oligonucleotides and CAMP4’s CMP-002 study
Editor's Picks
Newsletters and Deep Dive
digital magazine